Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$3.20 +1.6%	$2.31	$1.89 ▼ $3.68	$954.96M	0.36	3.16 million shs	7.07 million shs
CDXC ChromaDex		$6.16	$2.31 ▼ $9.18	$611.50M	2.21	813,359 shs	554,788 shs
ESPR Esperion Therapeutics	$1.17 -2.5%	$0.96	$0.69 ▼ $3.94	$231.89M	0.67	5.27 million shs	2.15 million shs
XNCR Xencor	$9.19 -2.5%	$9.06	$7.16 ▼ $27.24	$654.06M	0.87	667,610 shs	421,639 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	0.00%	+31.15%	+58.42%	+26.98%	-6.43%
CDXC ChromaDex	0.00%	0.00%	0.00%	+0.32%	+159.57%
ESPR Esperion Therapeutics	0.00%	-4.10%	+50.54%	-22.00%	-59.52%
XNCR Xencor	0.00%	-4.77%	+12.07%	-27.98%	-58.27%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABCL AbCellera Biologics	2.4538 of 5 stars	3.4	1.0	0.0	2.6	3.3	0.6
CDXC ChromaDex	2.5953 of 5 stars	3.5	0.0	4.0	0.6	0.0	1.9
ESPR Esperion Therapeutics	4.041 of 5 stars	3.3	3.0	3.9	2.7	1.7	0.6
XNCR Xencor	4.1174 of 5 stars	3.4	2.0	3.9	3.4	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	2.75	Moderate Buy	$8.33	160.42% Upside
CDXC ChromaDex	3.00	Buy	$9.03	∞ Upside
ESPR Esperion Therapeutics	2.50	Moderate Buy	$6.25	434.19% Upside
XNCR Xencor	2.75	Moderate Buy	$28.00	204.68% Upside

Current Analyst Ratings Breakdown

Latest ESPR, XNCR, ABCL, and CDXC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	ABCL AbCellera Biologics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $10.00
5/8/2025	XNCR Xencor	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$22.00 ➝ $6.00
5/7/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
4/30/2025	XNCR Xencor	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$31.00
4/25/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/25/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/21/2025	XNCR Xencor	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/17/2025	ESPR Esperion Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$4.00 ➝ $3.00
4/16/2025	ABCL AbCellera Biologics	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$4.00 ➝ $5.00
4/8/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/20/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$23.11M	41.32	N/A	N/A	$3.97 per share	0.81
CDXC ChromaDex	$99.60M	0.00	N/A	N/A	$0.38 per share	0.00
ESPR Esperion Therapeutics	$259.57M	0.89	N/A	N/A	($3.85) per share	-0.30
XNCR Xencor	$127.23M	5.14	N/A	N/A	$10.99 per share	0.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$146.40M	-$0.56	N/A	N/A	N/A	-533.32%	-15.73%	-12.22%	8/5/2025 (Estimated)
CDXC ChromaDex	-$4.94M	$0.10	787.29	0.00	N/A	1.62%	4.85%	2.70%	N/A
ESPR Esperion Therapeutics	-$209.25M	-$0.80	N/A	N/A	N/A	-29.37%	N/A	-10.77%	8/11/2025 (Estimated)
XNCR Xencor	-$126.09M	-$3.06	N/A	N/A	N/A	-232.77%	-30.92%	-21.74%	8/4/2025 (Estimated)

Latest ESPR, XNCR, ABCL, and CDXC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	ABCL AbCellera Biologics	-$0.17	-$0.15	+$0.02	-$0.15	$7.12 million	$4.24 million
5/8/2025	Q1 2025	XNCR Xencor	-$0.60	-$0.66	-$0.06	-$0.66	$23.44 million	$32.73 million
5/6/2025	Q1 2025	ESPR Esperion Therapeutics	-$0.18	-$0.21	-$0.03	-$0.21	$54.97 million	$65.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
CDXC ChromaDex	N/A	N/A	N/A	N/A	N/A
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	9.34	9.34
CDXC ChromaDex	N/A	2.95	2.35
ESPR Esperion Therapeutics	N/A	1.85	1.37
XNCR Xencor	0.01	6.23	6.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
CDXC ChromaDex	15.41%
ESPR Esperion Therapeutics	47.39%
XNCR Xencor	N/A

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.90%
CDXC ChromaDex	9.64%
ESPR Esperion Therapeutics	1.70%
XNCR Xencor	4.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	298.42 million	212.66 million	Optionable
CDXC ChromaDex	120	77.75 million	69.02 million	Optionable
ESPR Esperion Therapeutics	200	198.20 million	195.07 million	Optionable
XNCR Xencor	280	71.17 million	66.32 million	Optionable

ESPR, XNCR, ABCL, and CDXC Headlines

Recent News About These Companies

Analysts Set Xencor, Inc. (NASDAQ:XNCR) Target Price at $29.50

June 11, 2025 | americanbankingnews.com

Xencor (NASDAQ:XNCR) Trading Up 6.3% - Here's What Happened

June 10, 2025 | marketbeat.com

Bank of America Corp DE Sells 585,930 Shares of Xencor, Inc. (NASDAQ:XNCR)

June 9, 2025 | marketbeat.com

27,491 Shares in Xencor, Inc. (NASDAQ:XNCR) Acquired by Wellington Management Group LLP

June 8, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Moderate Buy" from Brokerages

June 8, 2025 | marketbeat.com

Public Employees Retirement System of Ohio Purchases New Holdings in Xencor, Inc. (NASDAQ:XNCR)

June 3, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Two Sigma Investments LP

May 27, 2025 | marketbeat.com

Nuveen Asset Management LLC Purchases 685,557 Shares of Xencor, Inc. (NASDAQ:XNCR)

May 26, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Holdings Lowered by Jane Street Group LLC

May 26, 2025 | marketbeat.com

Two Sigma Advisers LP Sells 130,900 Shares of Xencor, Inc. (NASDAQ:XNCR)

May 25, 2025 | marketbeat.com

Ameriprise Financial Inc. Has $6.72 Million Stake in Xencor, Inc. (NASDAQ:XNCR)

May 25, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Shares Acquired by RTW Investments LP

May 18, 2025 | marketbeat.com

Point72 Asset Management L.P. Sells 943,148 Shares of Xencor, Inc. (NASDAQ:XNCR)

May 18, 2025 | marketbeat.com

Northern Trust Corp Increases Holdings in Xencor, Inc. (NASDAQ:XNCR)

May 17, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Given Average Recommendation of "Moderate Buy" by Brokerages

May 16, 2025 | marketbeat.com

Jacobs Levy Equity Management Inc. Raises Stock Position in Xencor, Inc. (NASDAQ:XNCR)

May 15, 2025 | marketbeat.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Clover Health Investments (CLOV), Xencor (XNCR) and Intellia Therapeutics (NTLA)

May 13, 2025 | theglobeandmail.com

Xencor Reports First Quarter 2025 Financial Results

May 7, 2025 | uk.finance.yahoo.com

Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates

May 7, 2025 | zacks.com

Xencor, Inc. (NASDAQ:XNCR) EVP Nancy Valente Sells 4,616 Shares

May 7, 2025 | insidertrades.com

Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know

May 1, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESPR, XNCR, ABCL, and CDXC Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$3.20 +0.05 (+1.59%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$3.22 +0.02 (+0.63%)

As of 06/13/2025 07:54 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

ChromaDex NASDAQ:CDXC

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

Esperion Therapeutics NASDAQ:ESPR

$1.17 -0.03 (-2.50%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.19 +0.02 (+1.62%)

As of 06/13/2025 07:56 PM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Xencor NASDAQ:XNCR

$9.19 -0.24 (-2.55%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$9.18 0.00 (-0.05%)

As of 06/13/2025 04:04 PM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time